Kaplan-Meier estimates in 32 patients with WM treated with venetoclax monotherapy. PFS for the entire cohort (A), according to response depth (B), and CXCR4 mutational status (C). TFS for the entire cohort (D), according to response depth (E), and CXCR4 mutational status (F). MUT, mutant; WT, wild-type.
Figure 1.

Kaplan-Meier estimates in 32 patients with WM treated with venetoclax monotherapy. PFS for the entire cohort (A), according to response depth (B), and CXCR4 mutational status (C). TFS for the entire cohort (D), according to response depth (E), and CXCR4 mutational status (F). MUT, mutant; WT, wild-type.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal